HC Wainwright Initiates Coverage on Septerna (NASDAQ:SEPN)

HC Wainwright started coverage on shares of Septerna (NASDAQ:SEPN) in a research note published on Monday, MarketBeat Ratings reports. The firm issued a buy rating and a $26.00 target price on the stock. HC Wainwright also issued estimates for Septerna’s Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.72 EPS, Q4 2025 earnings at $0.68 EPS, FY2025 earnings at $1.01 EPS, Q1 2026 earnings at ($0.55) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.75) EPS and FY2026 earnings at ($2.46) EPS.

Several other research analysts have also commented on SEPN. Wells Fargo & Company boosted their price objective on shares of Septerna from $11.00 to $18.00 and gave the stock an “equal weight” rating in a research note on Friday, May 16th. Cantor Fitzgerald boosted their price objective on shares of Septerna from $20.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, May 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.75.

Septerna Trading Up 0.2%

NASDAQ SEPN opened at $10.73 on Monday. The company has a 50 day moving average price of $8.75 and a 200 day moving average price of $11.58. Septerna has a 52 week low of $4.17 and a 52 week high of $28.99.

Septerna (NASDAQ:SEPN) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The company had revenue of $0.22 million for the quarter. As a group, equities analysts forecast that Septerna will post -7.11 EPS for the current year.

Institutional Trading of Septerna

Several large investors have recently bought and sold shares of SEPN. Tower Research Capital LLC TRC purchased a new stake in Septerna during the 4th quarter worth approximately $25,000. New York State Common Retirement Fund purchased a new stake in Septerna during the 4th quarter worth approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Septerna in the 4th quarter valued at $42,000. Summit Investment Advisors Inc. purchased a new stake in shares of Septerna in the 4th quarter valued at $45,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in shares of Septerna in the 1st quarter valued at $49,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.